Chinese CDMO that manufactures small-molecule active ingredients and intermediates for global pharma and biotech under contract.
Chinese CDMO that manufactures small-molecule active ingredients and intermediates for global pharma and biotech under contract.
Customers hire it first to develop the manufacturing process for a drug in trials, which can lead to long commercial supply contracts if the drug is approved, so orders build over several years. COVID-treatment work temporarily boosted its sales during the pandemic. It is listed in both Shenzhen and Hong Kong.
In one line: A China-based Cambrex/Lonza for small-molecule APIs.
Moat: narrow (process know-how, customer qualification, regulatory licence). FDA/EMA-audited plants and validated processes make switching a qualified program costly.
Headquarters: Tianjin, China · Founded: 1995 · Employees: 10,617
Size Asymchem Laboratories (Tianjin) (002821.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $7.27B, the 322nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥141.21 on 18 Nov 2026.
Performance Over six months the shares gained 19.7%, against -0.4% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 18.1% over the last twelve months (peer median +8.5%); the operating margin is 17.2% (peer median 13.7%).
Valuation It trades at 37.4× forward earnings against a peer median of 19.2× (2nd most expensive of 16).
Capital Return on invested capital runs 1.6 points above its cost of capital (9.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥7.44B | CN¥6.64B | CN¥5.73B | CN¥7.78B | CN¥10.2B |
| Revenue growth | — | +16% | -26% | -24% | — |
| Gross profit | CN¥3.47B | CN¥2.64B | CN¥2.25B | CN¥3.83B | CN¥4.72B |
| EBITDA | n/a | CN¥1.61B | CN¥1.13B | CN¥2.70B | CN¥3.47B |
| Net income | CN¥1.18B | CN¥1.13B | CN¥949M | CN¥2.27B | CN¥3.30B |
| Free cash flow | -CN¥703M | CN¥330M | CN¥280M | CN¥2.51B | CN¥1.18B |
| Capital expenditure | CN¥1.84B | CN¥1.27B | CN¥1.13B | CN¥1.24B | CN¥2.15B |
| Total debt | CN¥689M | CN¥524M | CN¥475M | CN¥572M | CN¥585M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Asymchem Laboratories (Tianjin) 002821.SZ | $7.27B | +20% | +18% | 17% | 37.4× | n/a |
| WuXi AppTec 603259.SS | $64.2B | +40% | +32% | 43% | 17.0× | 7.2% |
| Porton Pharma Solutions 300363.SZ | $1.66B | +37% | +6% | -2% | n/a | 2.1% |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| Siegfried SFZN.SW | $3.51B | -17% | +4% | 16% | 16.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002821.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.0% | +2.2% | 6th lowest of 21 |
| 6-month return | +19.7% | -0.4% | 5th highest of 20 |
| Distance from 52-week high | -29.4% | -12.9% | 7th lowest of 21 |
| Revenue growth (TTM) | +18.1% | +8.5% | 6th highest of 19 |
| Operating margin | 17.2% | 13.7% | 6th highest of 20 |
| Forward P/E | 37.4× | 19.2× | 2nd most expensive of 16 |
| ROIC minus cost of capital | +1.6 pp | +1.7 pp | 9th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% | +6.6% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |